Michael A. Metzger

CIK: 0001507220

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (44.4%)

Position reduction

Option Exercises (M)4 (22.2%)

Derivative conversions

Awards (A)6 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

SNDX

Syndax Pharmaceuticals Inc

DirectorOfficer

PYXS

Pyxis Oncology, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (18 total)

SNDX
Syndax Pharmaceuticals Inc
Jul 8, 2026
Sale(S)
Direct
32.4K shares at avg. $24.24$785K
SNDX
Syndax Pharmaceuticals Inc
Jul 8, 2026
Exercise(M)
Direct
32.4K shares at avg. $6.38$207K
SNDX
Syndax Pharmaceuticals Inc
Jun 1, 2026
Sale(S)
Direct
6.8K shares at avg. $18.99$130K
PYXS
Pyxis Oncology, Inc.
Mar 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
45.9K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 9, 2026
Sale(S)
Direct
17.2K shares at avg. $21.03$361K
SNDX
Syndax Pharmaceuticals Inc
Feb 6, 2026
Sale(S)
Direct
7.4K shares at avg. $20.62$153K
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
144.6K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
73K shares-
SNDX
Syndax Pharmaceuticals Inc
Sep 8, 2025
Sale(S)
Direct
157.3K shares at avg. $16.41$2.6M
SNDX
Syndax Pharmaceuticals Inc
Sep 8, 2025
Exercise(M)
Direct
157.3K shares at avg. $10.90$1.7M
SNDX
Syndax Pharmaceuticals Inc
Jul 16, 2025
Sale(S)
Direct
7.5K shares at avg. $9.29$70K
PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
37K shares at avg. $0.98-
SNDX
Syndax Pharmaceuticals Inc
Mar 14, 2025
Exercise(M)
Direct
6.1K shares at avg. $7.20$44K
SNDX
Syndax Pharmaceuticals Inc
Mar 4, 2025
Exercise(M)
Direct
7.8K shares at avg. $7.20$56K
SNDX
Syndax Pharmaceuticals Inc
Mar 4, 2025
Sale(S)
Direct
7.8K shares at avg. $15.05$118K
SNDX
Syndax Pharmaceuticals Inc
Feb 10, 2025
Sale(S)
Direct
13.3K shares at avg. $15.50$206K
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
60.5K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
89K shares-

		Type	Shares	Price		Ownership
Jul 8, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	32,375	$24.24	$784,776	Direct
Jul 8, 2026	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	32,375	$6.38	$206,553	Direct
Jun 1, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	6,847	$18.99	$130,025	Direct
Mar 24, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	45,867	-	-	Direct
Feb 9, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	17,159	$21.03	$360,819	Direct
Feb 6, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	7,412	$20.62	$152,835	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	144,600	-	$0	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	73,000	-	$0	Direct
Sep 8, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	157,307	$16.41	$2,582,021	Direct
Sep 8, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	157,307	$10.90	$1,714,646	Direct
Jul 16, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	7,534	$9.29	$69,953	Direct
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	36,979	$0.98	-	Direct
Mar 14, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	6,074	$7.20	$43,733	Direct
Mar 4, 2025	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	7,814	$7.20	$56,261	Direct
Mar 4, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	7,814	$15.05	$117,564	Direct
Feb 10, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	13,288	$15.50	$206,017	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	60,500	-	-	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	89,000	-	-	Direct

1-18 of 18 transactions

About Metzger Michael A

Metzger Michael A (SEC CIK 0001507220) files insider reports with the SEC as Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX) and Director of Pyxis Oncology, Inc. (PYXS).

Signal8 holds 12 ownership filings by Metzger Michael A, all Form 4s, filed between Feb 7, 2025 and Jul 9, 2026. Those filings report 18 transactions, from Feb 5, 2025 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Metzger Michael A's filings is in NEW YORK, NY.

Recent filings by Metzger Michael A

Jul 8, 2026: Open-market sale of SNDX shares (Form 4, code S).
Jul 8, 2026: Option exercise of SNDX shares (Form 4, code M).
Jun 1, 2026: Open-market sale of SNDX shares (Form 4, code S).
Mar 24, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Feb 9, 2026: Open-market sale of SNDX shares (Form 4, code S).

Other insiders filing for Syndax Pharmaceuticals Inc (SNDX)

Podlesak Dennis, Director
Botwood Nicholas A.J., Head of R&D, CMO
Goldan Keith A., Chief Financial Officer
Jarrett Jennifer, Director
Huber Martin H. Jr., Director
Rizo Aleksandra, Director

How to read Form 4 transaction codes